A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation
Cancer Medicine · 2025
DOI: 10.1002/cam4.71220 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Takeo Fujii und 13 weiteren Autor:innen. Beteiligte Einrichtung: Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, AstraZeneca Durvalumab and olaparib were supplied to the NCI/C, AstraZeneca.
Abstract (Originalsprache)
Background
Immunostimulatory effects of PARP inhibitors could increase sensitivity to immune checkpoint inhibitors. The previous Phase II trial ( MEDIOLA ) reported clinical benefits of durvalumab and olaparib (D + O) in patients with germline BRCA ‐mutated ( gBRCAm ) HER2 ‐negative metastatic breast cancer. Yet, the clinical activity of D + O in germline BRCA wild‐type ( gBRCAwt ) triple‐negative breast cancer ( TNBC ) remains unknown.
Methods
This single‐arm Phase II study tested D + O in patients with metastatic TNBC . The primary objective was overall response rate ( ORR ). Secondary objectives were safety, disease control rate ( DCR ), progression‐free survival ( PFS ) and overall survival ( OS ). Based on gBRCA status, patients were assigned to either gBRCAwt or gBRCAm cohort and were treated with D (1500 mg iv q4w) and O (300 mg twice a day orally). Pretreatment fresh tissues and serial blood samples were collected for correlative studies.
Results
Fifteen patients (12 gBRCAwt and 3 gBRCAm ) were enrolled. gBRCAm and gBRCAwt cohorts are reported as a combined dataset because of small sample size due to COVID ‐19 and slow accrual. The median number of prior therapies was three (range 0–8). Among 14 RECIST ‐evaluable patients (11 gBRCAwt and 3 gBRCAm ), ORR was 28.6% (3 gBRCAm and 1 gBRCAwt ). DCR was 64.3% (3 gBRCAm and 6 gBRCAwt ). The median PFS and OS were 3.6 months (95% confidence interval [ CI ]: 1.8–5.7) and 10.7 months (95% CI : 5.9–38.9), respectively. There is one gBRCAm patient with ongoing durable PR (67.4+ months). There was no new safety concern. CD83 expression on Types 1 and 2 conventional dendritic cells in blood at baseline was low in the patients with PFS ≥ 4 months compared to those with PFS < 4 months.
Conclusion
Our study demonstrated modest clinical benefits of D + O with ORR of 28.6% in subsets of heavily pretreated TNBC . Further detailed classification of DCs to understand the predictive role of DCs and prospective validation in a large cohort is required. Trial Registration ClinicalTrials.gov identifier: NCT02484404
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Developmental Therapeutic Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Radiology and Imaging Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Collaborative Biostatistics Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Takeo Fujii, Ashley Cimino-Mathews, Stanley Lipkowitz, Min-Jung Lee, Jayakumar Nair, Alexandra Zimmer, Shraddha Rastogi, Nahoko Sato, Jung-Min Lee
Förderung
- Intramural NIH HHS
- AstraZeneca Durvalumab and olaparib were supplied to the NCI/C
- AstraZeneca
Zitieren
APA
Fujii, T., Cimino-Mathews, A., Lipkowitz, S., Lee, M. J., Nair, J., Solarz, B. B., Zimmer, A., Redd, B., Levy, E. B., Rastogi, S., Sato, N., McCoy, A., Steinberg, S. M., & Lee, J. M. (2025). A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation. Cancer Medicine. https://doi.org/10.1002/cam4.71220
Vancouver
Fujii T, Cimino-Mathews A, Lipkowitz S, Lee MJ, Nair J, Solarz BB, et al. A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation. Cancer Medicine. 2025. doi:10.1002/cam4.71220
BibTeX
@article{Fujii2025,
author = {Fujii, Takeo and Cimino-Mathews, Ashley and Lipkowitz, Stanley and Lee, Min-Jung and Nair, Jayakumar and Solarz, Britanny Brooke and Zimmer, Alexandra and Redd, Bernadette and Levy, Elliot B and Rastogi, Shraddha and Sato, Nahoko and McCoy, Ann and Steinberg, Seth M and Lee, Jung-Min},
title = {A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71220}
}
EUVIMED